N
Nyanda E. Ntinginya
Researcher at National Institute for Medical Research
Publications - 76
Citations - 1536
Nyanda E. Ntinginya is an academic researcher from National Institute for Medical Research. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 12, co-authored 47 publications receiving 1036 citations. Previous affiliations of Nyanda E. Ntinginya include Makerere University.
Papers
More filters
Journal ArticleDOI
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages.
David Stucki,David Stucki,Daniela Brites,Daniela Brites,Leïla Jeljeli,Mireia Coscolla,Mireia Coscolla,Qingyun Liu,Andrej Trauner,Andrej Trauner,Lukas Fenner,Lukas Fenner,Lukas Fenner,Liliana K. Rutaihwa,Liliana K. Rutaihwa,Sonia Borrell,Sonia Borrell,Tao Luo,Qian Gao,Midori Kato-Maeda,Marie Ballif,Marie Ballif,Marie Ballif,Matthias Egger,Rita Macedo,Helmi Mardassi,Milagros Moreno,Griselda Tudo Vilanova,Janet A. M. Fyfe,Maria Globan,Jackson Thomas,Frances B. Jamieson,Jennifer L. Guthrie,Adwoa Asante-Poku,Dorothy Yeboah-Manu,Eddie M. Wampande,Willy Ssengooba,Willy Ssengooba,Moses Joloba,W. Henry Boom,Indira Basu,James E. Bower,Margarida Saraiva,Sidra Ezidio Gonçalves Vasconcellos,Philip Noel Suffys,Anastasia Koch,Robert J. Wilkinson,Robert J. Wilkinson,Robert J. Wilkinson,Linda Gail-Bekker,Bijaya Malla,Bijaya Malla,Serej D. Ley,Serej D. Ley,Serej D. Ley,Hans-Peter Beck,Hans-Peter Beck,Bouke C. de Jong,Kadri Toit,Elisabeth Sanchez-Padilla,Maryline Bonnet,Ana Gil-Brusola,Matthias Frank,Véronique Penlap Beng,Kathleen D. Eisenach,Issam Alani,Perpetual Wangui Ndung'u,Gunturu Revathi,Florian Gehre,Florian Gehre,Suriya Akter,Francine Ntoumi,Lynsey Stewart-Isherwood,Nyanda E. Ntinginya,Andrea Rachow,Michael Hoelscher,Daniela Maria Cirillo,Girts Skenders,Sven Hoffner,Daiva Bakonyte,Petras Stakenas,Roland Diel,Valeriu Crudu,Olga Domnica Moldovan,Sahal Al-Hajoj,Larissa Otero,Francesca Barletta,E. Jane Carter,E. Jane Carter,Lameck Diero,Philip Supply,Iñaki Comas,Stefan Niemann,Sebastien Gagneux,Sebastien Gagneux +94 more
TL;DR: It is shown that lineage 4 comprises globally distributed and geographically restricted sublineages, suggesting a distinction between generalists and specialists, and further support a European origin for the most common generalist sublineage.
Journal ArticleDOI
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree,Norbert Heinrich,Rob E. Aarnoutse,Andreas H. Diacon,Rodney Dawson,Sunita Rehal,Gibson S. Kibiki,Gavin J. Churchyard,Gavin J. Churchyard,Ian Sanne,Nyanda E. Ntinginya,Lilian T. Minja,Robert D Hunt,Salome Charalambous,Madeleine Hanekom,Hadija H. Semvua,Stellah G. Mpagama,Christina Manyama,Bariki Mtafya,Klaus Reither,Klaus Reither,Robert S. Wallis,Amour Venter,Kim Narunsky,Anka Mekota,Sonja Henne,Angela Colbers,Georgette Plemper van Balen,Stephen H. Gillespie,Patrick P. J. Phillips,Michael Hoelscher +30 more
TL;DR: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens for the treatment of tuberculosis.
Journal ArticleDOI
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson,Andreas H. Diacon,Daniel Everitt,Christo van Niekerk,Peter R. Donald,Divan Aristo Burger,Divan Aristo Burger,Robert Schall,Robert Schall,Melvin Spigelman,Almari Conradie,Kathleen D. Eisenach,Amour Venter,Prudence Ive,Liesl Page-Shipp,Ebrahim Variava,Klaus Reither,Klaus Reither,Nyanda E. Ntinginya,Alexander Pym,Florian von Groote-Bidlingmaier,Mendel Carl M +21 more
TL;DR: A novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant tuberculosis during the first 8 weeks of treatment was investigated, and the combination of moxifloxacin, pretomanid, and pyrazinamide, was safe, well tolerated, and showed superior bactericidal activity.
Journal ArticleDOI
Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study
Damien Portevin,Damien Portevin,Felicien Moukambi,Petra Clowes,Asli Bauer,Mkunde Chachage,Nyanda E. Ntinginya,Elirehema Mfinanga,Khadija Said,Frederick Haraka,Andrea Rachow,Elmar Saathoff,Maximilian Mpina,Levan Jugheli,Levan Jugheli,Levan Jugheli,Fred Lwilla,Ben J. Marais,Michael Hoelscher,Claudia Daubenberger,Claudia Daubenberger,Klaus Reither,Klaus Reither,Klaus Reither,Christof Geldmacher +24 more
TL;DR: The sputum-independent TAM-TB assay is a rapid and accurate blood test that has the potential to improve the diagnosis of active tuberculosis in children.
Journal ArticleDOI
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Connor D. Tweed,Rodney Dawson,Divan Aristo Burger,Almari Conradie,Angela M. Crook,Mendel Carl M,Francesca Conradie,Andreas H. Diacon,Nyanda E. Ntinginya,Daniel Everitt,Frederick Haraka,Mengchum Li,Christo van Niekerk,Alphonse Okwera,Mohammed Rassool,Klaus Reither,Klaus Reither,Modulakgotla A. Sebe,Suzanne Staples,Ebrahim Variava,Melvin Spigelman +20 more
TL;DR: This multicentre, open-label, partially randomised, phase 2b trial aimed to investigate the bactericidal activity and safety profile of combinations of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in the first 8 weeks of treatment of pulmonary tuberculosis.